Bristol-Myers reports HIV data for BMS-663068

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from a Phase IIb trial evaluating BMS-663068 as add-on treatment for HIV-1 infection. In 251 treatment-experienced patients in the intent-to-treat population, BMS-663068 as add-on to raltegravir and tenofovir led to a response -- defined as HIV-1 RNA of less than 50 copies/mL at week 24, the primary endpoint -- in 69%-80% patients across all doses vs. 75% for BMS's Reyataz atazanavir and ritonavir plus raltegravir and tenofovir. Bristol-Myers said the trial was not powered for non-inferiority or superiority. The double-blind trial evaluated four doses of BMS-663068: 400 mg twice-daily, 800 mg twice-daily, 600 mg once-daily or 1,200 mg once-daily. Data were presented at the Conference on Retroviruses and Opportunistic Infections meeting in Seattle. Bristol-Myers said it plans to announce next steps for BMS-663068, an HIV-1 attachment inhibitor, "in the near future." ...